Telavancin Hydrochloride Patent Expiration

Telavancin Hydrochloride is Used for treating bacterial infections, including staphylococcal infections. It was first introduced by Cumberland Pharmaceuticals Inc in its drug Vibativ on Sep 11, 2009.


Telavancin Hydrochloride Patents

Given below is the list of patents protecting Telavancin Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Vibativ US7531623 Hydrochloride salts of a glycopeptide phosphonate derivative Jan 01, 2027 Cumberland
Vibativ US6635618 Glycopeptide phosphonate derivatives Sep 11, 2023

(Expired)

Cumberland
Vibativ US6858584 Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin Aug 24, 2022

(Expired)

Cumberland
Vibativ US6872701 Glycopeptide phosphonate derivatives Jun 05, 2021

(Expired)

Cumberland
Vibativ US7008923 Glycopeptide phosphonate derivatives May 06, 2021

(Expired)

Cumberland
Vibativ US7208471 Glycopeptide phosphonate derivatives May 01, 2021

(Expired)

Cumberland
Vibativ US7351691 Glycopeptide phosphonate derivatives May 01, 2021

(Expired)

Cumberland
Vibativ US7544364 Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin May 01, 2021

(Expired)

Cumberland
Vibativ US7700550 Glycopeptide phosphonate derivatives May 01, 2021

(Expired)

Cumberland
Vibativ US8101575 Glycopeptide phosphonate derivatives May 01, 2021

(Expired)

Cumberland
Vibativ US8158580 Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin May 01, 2021

(Expired)

Cumberland



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Telavancin Hydrochloride's patents.

Given below is the list recent legal activities going on the following patents of Telavancin Hydrochloride.

Activity Date Patent Number
Patent litigations
Expire Patent 20 May, 2024 US8158580
Expire Patent 26 Feb, 2024 US8101575
Maintenance Fee Reminder Mailed 04 Dec, 2023 US8158580
Maintenance Fee Reminder Mailed 11 Sep, 2023 US8101575
Expire Patent 23 May, 2022 US7700550
Maintenance Fee Reminder Mailed 06 Dec, 2021 US7700550
Payment of Maintenance Fee, 12th Year, Large Entity 24 Sep, 2020 US7544364
Payment of Maintenance Fee, 12th Year, Large Entity 24 Sep, 2020 US7531623
Payment of Maintenance Fee, 8th Year, Large Entity 04 Oct, 2019 US8158580
Payment of Maintenance Fee, 12th Year, Large Entity 20 Sep, 2019 US7351691


Telavancin Hydrochloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List